Literature DB >> 28465731

Measurement of Serum Superoxide Dismutase and Its Relevance to Disease Intensity Autistic Children.

Mozhgan Afrazeh1, Sakineh Saedisar1, Mohammad Reza Khakzad2, Maryam Hojati3.   

Abstract

BACKGROUND: Autism is a pervasive disorder and its prevalence increased in recent surveys. An estimated 1 out of every 88 children is affected by autism. Autism disorder symptoms appear before the age of three. It is believed that serum levels of superoxide dismutase may play a role in etiology of autism.
MATERIALS AND METHODS: Between October and November 2014, 27 Iranian children from Mashhad city were selected in this study. Given these assumptions, the amount of SOD serum in autistic patients and healthy individuals and correlation between the amount of SOD and autism severity were examined. Blood samples of 30 autistic children and 18 age-matched healthy children were collected between 9 to 11 am. Serum level of SOD in both groups was measured by ELISA method.
RESULTS: The mean SOD level in the treatment group (1.04 ±1.33 ng/ml) was significantly lower than the control group (p = 0.001). However, SOD level was not significantly associated with the autism severity (p = 0.667). Conclusions: Decreased serum levels of superoxide dismutase in the early diagnosis of autistic children can be considered as a diagnostic biomarker.

Entities:  

Year:  2015        PMID: 28465731      PMCID: PMC5394433     

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN: 1841-9038


  10 in total

Review 1.  Risk factors for autism: translating genomic discoveries into diagnostics.

Authors:  Stephen W Scherer; Geraldine Dawson
Journal:  Hum Genet       Date:  2011-06-24       Impact factor: 4.132

2.  Brain region-specific changes in oxidative stress and neurotrophin levels in autism spectrum disorders (ASD).

Authors:  Elizabeth M Sajdel-Sulkowska; Ming Xu; Woody McGinnis; Noriyuki Koibuchi
Journal:  Cerebellum       Date:  2011-03       Impact factor: 3.847

Review 3.  Air pollution, oxidative stress and dietary supplementation: a review.

Authors:  I Romieu; F Castro-Giner; N Kunzli; J Sunyer
Journal:  Eur Respir J       Date:  2008-01       Impact factor: 16.671

4.  Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS).

Authors:  E Schopler; R J Reichler; R F DeVellis; K Daly
Journal:  J Autism Dev Disord       Date:  1980-03

Review 5.  Sex differences in autism spectrum disorders.

Authors:  Donna M Werling; Daniel H Geschwind
Journal:  Curr Opin Neurol       Date:  2013-04       Impact factor: 5.710

Review 6.  Pervasive developmental disorders and psychosis.

Authors:  Jean Starling; David Dossetor
Journal:  Curr Psychiatry Rep       Date:  2009-06       Impact factor: 5.285

Review 7.  Global prevalence of autism and other pervasive developmental disorders.

Authors:  Mayada Elsabbagh; Gauri Divan; Yun-Joo Koh; Young Shin Kim; Shuaib Kauchali; Carlos Marcín; Cecilia Montiel-Nava; Vikram Patel; Cristiane S Paula; Chongying Wang; Mohammad Taghi Yasamy; Eric Fombonne
Journal:  Autism Res       Date:  2012-04-11       Impact factor: 5.216

Review 8.  Autism risk factors: genes, environment, and gene-environment interactions.

Authors:  Pauline Chaste; Marion Leboyer
Journal:  Dialogues Clin Neurosci       Date:  2012-09       Impact factor: 5.986

9.  Decreased Serum Cu/Zn SOD Associated with High Copper in Children with Attention Deficit Hyperactivity Disorder (ADHD).

Authors:  A J Russo
Journal:  J Cent Nerv Syst Dis       Date:  2010-05-04

10.  Role of NAD(+), Oxidative Stress, and Tryptophan Metabolism in Autism Spectrum Disorders.

Authors:  Musthafa Mohamed Essa; Selvaraju Subash; Nady Braidy; Samir Al-Adawi; Chai K Lim; Tamilarasan Manivasagam; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2013-07-21
  10 in total
  1 in total

1.  Kynurenine and oxidative stress in children having learning disorder with and without attention deficit hyperactivity disorder: possible role and involvement.

Authors:  Ayman Kilany; Neveen Hassan Nashaat; Hala M Zeidan; Adel F Hashish; Mostafa M El-Saied; Ehab Ragaa Abdelraouf
Journal:  BMC Neurol       Date:  2022-09-20       Impact factor: 2.903

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.